This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.» Read More
SEOUL, April 1- South Korea will allow certain levels of animal feed additive zilpaterol in beef from June, a government official said on Tuesday, opening the door to imports of some meat containing the growth enhancer and its domestic sale.
March 31- Prana Biotechnology Ltd lost nearly three-quarters of its value after the company said its experimental drug to treat Alzheimer's disease failed a mid-stage study, raising doubts about the drug's future.
Some of the names on the move ahead of the open.
March 26- Merck and Co Inc and GlaxoSmithKline Plc are not reimbursing drug co-payments for patients who purchase their health insurance through state and federal exchanges set up under the Obamacare program.
U.S. stocks fell on Wednesday as Ukraine back in focus.
*Sanofi hopes to deliver first doses in late 2015. *Sanofi has spent over 1.3 bln euros on project.
U.S. stocks fell on Monday.
March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 8 percent, Amgen Inc dropped 3 percent and Celgene Corp lost 3.7 percent.
CAIRO/ LONDON, March 21- Gilead Sciences, facing mounting criticism over the high price of its new hepatitis C pill Sovaldi, has offered to supply the medicine to Egypt at a 99 percent discount to the U.S. price.
March 21- U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug Sovaldi, which is encountering resistance from health insurers and state Medicaid programs. Biogen Idec fell 6 percent, Amgen Inc dropped 2.5 percent and Celgene Corp was down 2 percent.
March 21- Endocyte Inc's shares more than doubled after the company said its cancer drug was recommended for conditional approval in Europe for ovarian cancer and that the drug improved survival rates in lung cancer patients.
March 21- Endocyte Inc said its experimental drug improved survival rates in lung cancer patients without the disease worsening, when used in combination with an approved treatment.
Among companies named in the study were aerospace group Boeing Co, drugmaker Merck& Co Inc and industrial group Rockwell Automation Inc.. Some states did not collect corporate taxes in the years CTJ examined, including Washington State, where Boeing was founded.
*Novartis reviewing fate of animal health, vaccines and OTC units. BASEL, Switzerland, March 20- Novartis Chief Executive Joe Jimenez is taking a hard look at the drugmaker's smaller businesses as he reshapes the company for what he expects to be a "brutal" new era in healthcare spending.
*MAGE-A3 fails to hit goal in Phase III lung cancer trial. March 20- An experimental cancer vaccine from GlaxoSmithKline has failed in a second test- this time against lung cancer- but the British company said it still hoped to identify a sub-group of patients in which it would work.
March 20- An experimental cancer vaccine from GlaxoSmithKline has failed in a second test- this time against lung cancer- but the British group said it still hoped to find a sub-group of patients in which it would work.
If you’re looking to build a portfolio of stocks, here’s how Cramer would put money to work right here and right now.
March 14- An experimental Amgen Inc cancer vaccine used to treat advanced melanoma, the deadliest form of skin cancer, proved effective in a late-stage study in shrinking tumors in a way that suggests the drug triggered the intended systemic immune response, according to data presented on Friday.
The "Fast Money" traders share their final trades of the day.
March 12- The number of U.S. cattle deaths that may be linked to the Merck& Co Inc feed additive Zilmax are much higher than the figures reported by the drug company to the federal government, according to a research study published on Wednesday.